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Maternal folic acid (FA) supplementation before and in early pregnancy prevents
neural tube defects (NTD), but it is uncertain whether continuing FA after the first
trimester has benefits on offspring health. We aimed to evaluate the effect of FA
supplementation throughout pregnancy on cognitive performance and brain function in
the child.
Methods
Follow-up investigation of 11-year old children, residing in Northern Ireland, whose
mothers had participated in a randomised trial of Folic Acid Supplementation in the
Second and Third Trimesters (FASSTT) in pregnancy and received 400 µg/d FA or
placebo from the 14th gestational week. Cognitive performance (Full Scale Intelligence
Quotient, Verbal Comprehension, Working Memory, Perceptual Reasoning, and
Processing Speed) was assessed using the Wechsler Intelligence Scale for Children.
Neuronal function was assessed using magnetoencephalographic (MEG) brain
imaging.
Results
Of 119 mother-child pairs in the FASSTT trial, 68 children were assessed for
neurocognitive performance at 11-year follow-up (Dec 2017 to Nov 2018). Children of
mothers randomised to FA compared with placebo scored significantly higher in two
Processing Speed tests i.e. symbol search (mean difference 2.9 points, 95% CI 0.3 to
5.5, p=0.03) and cancellation (11.3 points, 2.5 to 20.1, p=0.04), whereas the positive
effect on Verbal Comprehension was significant in girls only (6.5 points, 1.2 to 11.8,
p=0.03). MEG assessment of neuronal responses to a language task showed
increased power at the Beta (13-30 Hz, p=0.01) and High Gamma (49-70 Hz, p=0.04)
bands in children from FA-supplemented mothers, suggesting more efficient semantic
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
processing of language.
Conclusions
Continued FA supplementation in pregnancy beyond the early period currently
recommended to prevent NTD, can benefit neurocognitive development of the child.
MEG provides a non-invasive tool in paediatric research to objectively assess
functional brain activity in response to nutrition and other interventions.
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Abstract  26 
Background: Maternal folic acid (FA) supplementation before and in early pregnancy prevents 27 
neural tube defects (NTD), but it is uncertain whether continuing FA after the first trimester has 28 
benefits on offspring health. We aimed to evaluate the effect of FA supplementation throughout 29 
pregnancy on cognitive performance and brain function in the child. 30 
Methods: Follow-up investigation of 11-year old children, residing in Northern Ireland, whose 31 
mothers had participated in a randomised trial of Folic Acid Supplementation in the Second and 32 
Third Trimesters (FASSTT) in pregnancy and received 400 µg/d FA or placebo from the 14th 33 
gestational week. Cognitive performance (Full Scale Intelligence Quotient, Verbal 34 
Comprehension, Working Memory, Perceptual Reasoning, and Processing Speed) was assessed 35 
using the Wechsler Intelligence Scale for Children. Neuronal function was assessed using 36 
magnetoencephalographic (MEG) brain imaging.  37 
Results: Of 119 mother-child pairs in the FASSTT trial, 68 children were assessed for 38 
neurocognitive performance at 11-year follow-up (Dec 2017 to Nov 2018). Children of mothers 39 
randomised to FA compared with placebo scored significantly higher in two Processing Speed 40 
tests i.e. symbol search (mean difference 2.9 points, 95% CI 0.3 to 5.5, p=0.03) and cancellation 41 
(11.3 points, 2.5 to 20.1, p=0.04), whereas the positive effect on Verbal Comprehension was 42 
significant in girls only (6.5 points, 1.2 to 11.8, p=0.03). MEG assessment of neuronal responses 43 
to a language task showed increased power at the Beta (13-30 Hz, p=0.01) and High Gamma (49-44 
70 Hz, p=0.04) bands in children from FA-supplemented mothers, suggesting more efficient 45 
semantic processing of language. 46 
Conclusions: Continued FA supplementation in pregnancy beyond the early period currently 47 
recommended to prevent NTD, can benefit neurocognitive development of the child. MEG 48 
provides a non-invasive tool in paediatric research to objectively assess functional brain activity 49 



































































Trial registration: ISRCTN ISRCTN19917787. Registered 15 May 2013. 51 
Key words: Prenatal folic acid, Pregnancy, Randomised controlled trial, Child cognition, 52 
Neuronal function, Wechsler Intelligence Scale for Children, Magnetoencephalographic brain 53 
imaging.  54 
 55 
Background   56 
Folate is essential in early life, with conclusive evidence that periconceptional supplementation 57 
with folic acid (FA; the synthetic vitamin form) is effective in preventing the first occurrence [1] 58 
and recurrence [2] of neural tube defects. This evidence has led to recommendations that are in 59 
place worldwide for women to take FA from before conceiving until the end of the first trimester. 60 
What is less clear is whether continued FA supplementation after the first trimester of pregnancy 61 
can confer longer term health benefits to the child. Emerging evidence however shows that the 62 
period of rapid growth and development of the fetal brain occurring in later pregnancy is 63 
particularly sensitive to maternal folate concentrations [3]. Also, myelination of the brain, which 64 
is most intensive from mid-gestation to the second year of life [4] and essential for cognitive 65 
development as it protects nerve axons and facilitates communication between neurons, may be 66 
particularly vulnerable to deficiency of folate [5]. Several studies have investigated the 67 
association of maternal folate in pregnancy with neurocognitive development in the child [6]. 68 
Over 40 years ago, Gross et al. showed that children born to mothers diagnosed with folate-69 
related megaloblastic anaemia in the third trimester of pregnancy had abnormal 70 
neurodevelopment and lower intellectual abilities, compared to infants born to mothers with 71 
optimal folate status [7]. Decades later, a longitudinal transgenerational study found that optimal 72 
maternal folate status during later pregnancy was associated with better cognitive performance 73 
in the child at 9-10 years [8]. Another study of note used magnetic resonance imaging (MRI) of 74 



































































pregnancy was associated with, not only lower language and visuospatial abilities, but also 76 
reduced brain volumes in children aged 6-8 years [9]. 77 
A major limitation in the aforementioned studies is that they are observational and thus, 78 
by design, cannot demonstrate that maternal folate nutrition is causatively linked with cognitive 79 
outcomes in the offspring [6]. More robust evidence was however provided in our recent follow-80 
up study of children whose mothers had participated in a randomised trial of Folic Acid 81 
Supplementation in the Second and Third Trimesters (FASSTT) [10], and showed improved 82 
psychometrically measured cognition at 3 years and word reasoning (verbal IQ) at 7 years in the 83 
children of mothers randomised to receive FA in pregnancy [11]. The latter study, and almost all 84 
previous research in this area, involved psychological tests to assess neurodevelopment in 85 
children, whereas direct measurements of neuronal activity in the brain have rarely been 86 
employed. Magnetoencephalography (MEG) is a non-invasive neuroimaging modality that 87 
measures the magnetic fields associated with neuronal currents generated by the brain and may 88 
thus provide a robust platform for investigating neurodevelopment in children [12]. Therefore, 89 
in the present FASSTT Offspring trial, we aimed to evaluate the effect of FA supplementation 90 
during pregnancy on cognitive performance and MEG-assessed brain functioning in the child at 91 
11 years. Our hypothesis was that the higher verbal IQ previously found in the 7-year old children 92 
of mothers randomised to receive FA in pregnancy would remain evident in these children at 11 93 
years, as measured by both cognitive testing and MEG assessment.   94 
 95 
Methods  96 
Study population 97 
This study was conducted as a follow-up investigation of children at 11 years whose mothers 98 
participated in the FASSTT trial in pregnancy, as described in detail elsewhere [10]. Briefly, 99 



































































400µg/d of FA in the first trimester (as per current guidelines in the UK), were recruited from 101 
antenatal clinics in Northern Ireland before the 14th gestational week (GW). Women were 102 
excluded from participation in the trial if they had a previous NTD-affected pregnancy or were 103 
taking medications known to interfere with folate or related B-vitamin metabolism. Among the 104 
inclusion criteria were taking FA supplements sometime in the 1st trimester at the recommended 105 
use of 400 µg/day; this automatically excluded any mother taking no FA or taking higher dose 106 
FA. At the start of the second trimester, pregnant women were stratified into tertiles of plasma 107 
homocysteine (a functional marker of folate status) and subjects in each stratum were randomized 108 
to receive FA (400µg/d) or placebo until the end of pregnancy (i.e. a total intervention 26 weeks). 109 
FA supplements were distributed (in 7-day pillboxes) to participants every 4 weeks and an overall 110 
participant compliance rate of 93% was estimated from records of unused tablets.  111 
The current FASSTT Offspring study was conducted from December 2017 to November 112 
2018, when the child was 11 years old (Fig 1). Mother-child pairs were recruited by invitation 113 
letter to attend an appointment at the Nutrition Innovation Centre for Food and Health (NICHE), 114 
Ulster University. All efforts were made to recruit the maximum number of participants from the 115 
original FASSTT trial. If current contact details were not readily available from our research 116 
records, the details were traced through health records. Those who failed to attend for 117 
appointment were offered an alternative date, up to a maximum of five appointments. A 118 
participant information sheet was provided to the mother, whilst a child-friendly version was 119 
provided to explain the study to the child. In compliance with ethical requirements, signed 120 
informed consent from the mother and assent from the child were obtained at the beginning of 121 
the appointment. Ethical approval was granted by the Office for Research Ethics Committees 122 
Northern Ireland (ORECNI Ref: 12/NI/0077) and the study was registered 123 




































































Fig. 1 Diagrammatic protocol of the FASSTT Offspring Trial at 11 years 126 
 127 
Scale for intellectual development evaluation 128 
Cognitive performance of the child was assessed by the Wechsler Intelligence Scale for Children 129 
4th UK Edition (WISC-IV) using Q-interactive™ software (Pearson Education Ltd, UK) and 130 
performed using iPads [13]. The WISC-IV assessment is suitable for children from 6 years to 16 131 
years and 11 months and provides composite scores for specified cognitive IQ domains - Verbal 132 
Comprehension, Perceptual Reasoning, Working Memory and Processing Speed comprising 15 133 
subtests - which are combined to give one composite score that represents the child’s general 134 
intellectual ability (Full Scale IQ). The assessment of each child lasted 90-120 minutes and the 135 
entire test battery was completed in one session. To ensure an ideal environment for assessment 136 
of the child, the room was bright, ventilated and free from distraction and interruptions. The same 137 
trained researcher (AC) conducted the assessments of all children and was blinded to the 138 
treatment allocation of the mother during the FASSTT trial. 139 
 140 
Magnetoencephalography acquisition and analysis 141 
In a sub-sample of participants, MEG brain imaging was performed in the Northern Ireland 142 
Functional Brain Mapping (NIFBM) facility at the Intelligent Systems Research Centre, Ulster 143 
University. Before beginning the MEG task, participants were given verbal instructions and 144 
watched a child-friendly video to explain MEG, as produced by Aston University [14]. Once in 145 
the MEG machine, the children were encouraged to remain as still as possible and were provided 146 
with earphones, asked to listen carefully and to try to understand the sentences. Eye movements 147 
and heartbeat rhythm were monitored by bipolar electrodes. Head movement was recorded using 148 
head-position indicator (HPI) equipment with coils placed on the scalp. For each participant, 149 



































































scans were performed for individual brain structures, in order to provide anatomically informed 151 
MEG analysis, the HPI digitisation points were realigned to the individual head shape for each 152 
participant and then registered to the recorded MEG data.  153 
Based on our previous findings showing higher word reasoning scores (verbal IQ) at 7 154 
years in the children of FASSTT trial participants randomised to receive FA in pregnancy [11], 155 
and observational evidence linking maternal folate deficiency in pregnancy with lower language 156 
abilities in the child [9], a language task was selected to test the underlying neurophysiological 157 
basis of language processing in this study using MEG.  For this purpose, we adapted a high level 158 
semantic language task [15] to compare the difference in neural responses to two types of 159 
sentences, which are rendered either congruent or incongruent at the presentation of the final 160 
word. (for e.g, ‘The baby was thirsty and wanted a drink of milk/fire, where ‘fire’ or ‘milk’ 161 
renders the sentence semantically incongruent, or congruent, respectively): (Additional File 1: 162 
Methods). The MEG responses were recorded with the Elekta Neuromag 306-channel MEG 163 
system (using the operating conditions as detailed in Additional File 1: Methods). The band 164 
power in response to the language paradigm was obtained from 116 brain regions and averaged 165 
within six standard spectral bands: Big band [1 –48Hz], Theta [4–8Hz], Mu [8–12Hz], Beta [13–166 
30Hz], Low Gamma [30–48Hz] and High Gamma [49–70Hz].  167 
 168 
Data collection: related covariates 169 
General health and lifestyle measures 170 
Health and lifestyle information was gathered from the mother using a detailed questionnaire that 171 
included information on socioeconomic status which was mapped using house number, street 172 
name, postcode, town, and the Land and Property Services Ordnance Survey of Northern Ireland 173 
POINTER Geo-referencing database [16]. After verifying the address information, all 174 



































































Output Area in which they lived and using data from the Northern Ireland Multiple Deprivation 176 
Measure 2010 (MDM) score [17].  177 
Standardised calibrated equipment was used to measure height (portable stadiometer, 178 
SECA, Birmingham); head and waist circumference (non-stretchable tape); weight and body 179 
fatness (TANITA, TBF-410, Netherlands). BMI Z-scores were calculated using World Health 180 
Organization AnthroPlus software for assessing growth in children and adolescents of 5-19 years 181 
[18].  182 
 183 
Blood sampling and B-vitamin biomarkers 184 
As previously detailed, non-fasting blood samples were collected from the mother at 14th and 185 
36th GW, and umbilical cord blood was collected at delivery [10]. For the current study, a 186 
paediatric phlebotomist obtained non-fasting blood samples from the child at 11 years. All blood 187 
processing was carried out within 4h of collection and stored at -80℃ until analysis. Samples 188 
were analysed for serum and RBC folate, serum vitamin B12 and plasma homocysteine using 189 
standard methods, and riboflavin status was determined using the erythrocyte glutathione 190 
reductase activation coefficient (EGRac) assay, as described elsewhere [19]. For each assay, 191 
quality controls were provided by the repeated analysis of pooled samples covering a wide range 192 
of values. Intraassay and interassay CVs were ≤8.2% for RBC folate, ≤10.4% for serum vitamin 193 
B12, ≤2.5% for plasma homocysteine, and ≤2.8% for EGRac. Genotype for the common C677T 194 
polymorphism in the gene encoding methylenetetrahydrofolate reductase (MTHFR) was 195 
identified using polymerase chain reaction amplification, followed by HinF1 digestion.  196 
 197 
Dietary analysis 198 
Dietary intakes were evaluated using a 4-d food diary (which included 2 weekdays and 2 199 



































































validated for folate and related B-vitamin intakes against biomarker values, as described in detail 201 
elsewhere [20]. Vitamin supplement use was also recorded. Nutrient intakes were analysed using 202 
the Nutritics nutritional software package [21], which was customised to include the most recent 203 
nutritional content of fortified food products.  204 
 205 
Statistical analysis 206 
Confirmation that the sample size remained appropriate for cognitive performance testing was 207 
based on the assessment scores in the WPPSI-III test from these children previously sampled at 208 
7 years [11]. A sample size of 37 children in each group was estimated to detect a significant 209 
difference in cognitive performance between the children of mothers randomised to FA versus 210 
placebo during pregnancy, with a power of 80% at α=0.05.  211 
Statistical analysis was performed using the Statistical Package for the Social Sciences 212 
software (version 25.0; SPSS UK Ltd. Chertsey, UK). Data not normally distributed were log 213 
transformed before analysis. Differences between placebo and treatment groups were analysed 214 
using independent t tests for linear variables and χ2 tests for categorical parameters. Raw 215 
cognitive scores were automatically standardised for the child’s age at time of testing, and 216 
appropriate age-specific reference intervals were applied in adherence with test protocols. 217 
Analysis of covariance (ANCOVA) was used to test for differences in cognitive test variables 218 
and MEG power (semantic processing efficiency) between treatment groups, with adjustment for 219 
relevant confounding factors, including socioeconomic status (MDM score) [22] and child’s sex 220 
[23]. In all analyses, a 2-sided p value <0.05 was considered significant. 221 
 222 
Results  223 



































































Of the 119 participants in the FASSTT trial [10], 68 mother-child pairs completed the FASSTT 225 
Offspring trial at 11 years, representing a 57% response rate. Maternal characteristics, including 226 
biomarker responses to intervention with FA or placebo during pregnancy, were similar for 227 
mothers participating in the current study as compared with the total sample in the original trial 228 
(Additional File 1: Table S1). No adverse events were reported at any time during the original 229 
FASSTT trial or the follow-up studies of mother-child pairs. 230 
Maternal, neonatal and child health characteristics are reported in Table 1, showing no 231 
significant differences in general characteristics between the FA and placebo groups. In mothers 232 
during pregnancy, there were also no significant differences between the treatment groups in 233 
serum or RBC folate at the 14th GW (pre-intervention), but after FA intervention for 26 weeks, 234 
these folate biomarkers were significantly higher in the FA group in maternal (at 36 GW) and in 235 
cord blood samples (Table 2). In children at 11 years, there were no significant differences 236 
between the treatment groups in dietary intakes or biomarkers of folate or metabolically related 237 
B-vitamins. Mean dietary folate and B-vitamin intakes compared favourably with European Food 238 
Safety Authority (EFSA) population reference intake (PRI) values for children 11-14 years [24], 239 
and B-vitamin biomarker concentrations were in good agreement with those reported in 240 
population-based surveys in children from Norway [25], the UK [26] and the USA [27]. 241 
 242 
Table 1 General characteristics of mother-child pairs from the FASSTT Offspring trial 243 
 Placebo (n = 31) Folic Acid (n = 37) 
Maternal characteristics at 14th GW   
  Age, y 28.1 (26.6, 29.6) 29.7 (28.5, 30.8) 
  BMI, kg/m2 25.2 (23.7, 26.7) 25.5 (23.6, 27.3) 
  Smoker, No. (%) 2 (6) 5 (14) 
  Duration of FA use at sampling, wka 13.3 (10.5, 16.0) 12.7 (10.3, 15.0) 
  Iron supplement use, No. (%) 6 (19) 11 (30) 
  Parity, No. 0.7 (0.4, 1.0) 0.9 (0.6, 1.2) 
  Caesarean section, No. (%) 9 (29) 10 (27) 



































































Married, No. (%) 24 (80) 33 (92) 
Owner of dwelling, No. (%) 24 (80) 30 (83)  
Rural dweller, No. (%) 16 (52) 22 (59) 
Socioeconomic status (MDM score)b 21.9 (17.0, 26.8) 18.7 (15.3, 22.0) 
Neonatal characteristics   
  Gestational age, wk 40.2 (39.6, 40.7) 39.8 (39.4, 40.2) 
  Sex, male, No. (%) 15 (48) 16 (43) 
  Birth weight, g 3503 (3329, 3677) 3461 (3290, 3633) 
  Birth length, cm 51.1 (50.2, 52.0) 50.9 (50.1, 51.7) 
  Head circumference, cm 34.5 (34.0, 35.0) 34.6 (34.1, 35.1) 
  Apgar score at 1 min 8.4 (7.9, 8.8) 8.4 (8.0, 8.8) 
  Apgar score at 5 min 8.9 (8.8, 9.1) 8.9 (8.7, 9.1) 
  Breastfed, No. (%) 15 (48) 16 (43) 
Child characteristics (11 years)   
  Age, y 10.8 (10.7, 10.8) 10.8 (10.7, 11.0) 
  Siblings, No. 1.9 (1.5, 2.3) 1.7 (1.5, 2.0) 
  Weight, kg 39.3 (35.8, 42.8) 37.7 (35.3, 40.1) 
  Height, cm 147.1 (144.8, 149.3) 146.7 (144.0, 149.3) 
  BMI for age z scorec  0.15 (-0.33, 0.62) -0.03 (-0.45, 0.38) 
  Waist circumference, cm 71.1 (67.3, 74.9) 68.2 (65.6, 70.7) 
  Head circumference, cm 55.2 (54.2, 56.2) 54.7 (54.0, 55.4) 
  Body fatness, % 19.6 (15.8, 23.3) 19.2 (16.5, 21.9) 
Continuous measures presented as mean (95% CI), unless otherwise indicated. Categorical 244 
measures compared using Pearson’s chi-square, as appropriate. 245 
aThe duration of FA use refers to the total number of weeks, from initiating FA supplements to 246 
time of sampling at the 14th gestational week of pregnancy. 247 
bNorthern Ireland Multiple Deprivation Measure 2010 (MDM). This is a measure of 248 
socioeconomic area-based deprivation and comprises 7 domains, each developed to measure 249 
a distinct form of deprivation: income, employment, health, education, proximity to services, 250 
living environment, and crime.  251 
cZ scores for BMI were calculated using the WHO AnthroPlus software [18].  252 
 253 
Table 2 Folate and related B-vitamin status of mother-child pairs from the FASSTT Offspring trial 254 
  Placebo (n = 31) Folic Acid (n = 37) p value
 
Mothers during pregnancy     
Preintervention (14th gestational week)     
  Dietary intakes      
    Energy, MJ/d  8.463 (7.631, 9.296) 7.995 (7.468, 8.522) 0.31 
    Dietary folate equivalents, µg/d  371 (306, 437) 388 (329, 447) 0.71 
  B vitamin status     



































































    RBC folate, nmol/L  1055 (839, 1271) 1271 (1059, 1482) 0.15 
    Serum B12, pmol/L  236 (209, 264) 233 (206, 259) 0.85 
    Plasma homocysteine, µmol/L  6.1 (5.6, 6.6) 6.1 (5.6, 6.6) 0.96 
    MTHFR 677TT genotype, No. (%)  4 (13) 5 (14) 0.91 
Postintervention (36th GW)     
    Serum folate, nmol/L  22.4 (15.9, 28.8) 52.9 (45.8, 60.0) <0.001 
    RBC folate, nmol/L  907 (722, 1042) 1864 (1650, 2078) <0.001 
    Serum B12, pmol/L  169 (151, 188) 175 (152, 198) 0.98 
    Plasma homocysteine, µmol/L  7.2 (6.5, 7.9) 6.3 (5.8, 6.8) 0.04 
Neonates at birth     
  Serum folate, nmol/L  68.2 (57.8, 78.5) 105.2 (93.4, 117.0) <0.001 
  RBC folate, nmol/L  1512 (1272, 1752) 2216 (1856, 2575) 0.001 
  Serum B12, pmol/L  286 (230, 342) 259 (216, 302) 0.42 
  Plasma homocysteine, µmol/L  9.6 (7.7, 11.4) 10.4 (8.9, 11.9) 0.35 
  MTHFR 677TT genotype, No. (%)  3 (13) 4 (13) 0.99 
Children at 11 years     
Vitamin supplement user, No. (%)  9 (30) 8 (22) 0.62 
Fortified food consumer, No. (%)  28 (93) 33 (89) 0.87 
Dietary intakesa  PRIc    
  Energy, MJ/d 6.400 6.676 (6.118, 7.234) 6.746 (6.088, 7.404) 0.87 
  Dietary folate equivalents, µg/d 270 276 (234, 317) 265 (232, 299) 0.66 
  Vitamin B12, µg/d 3.5 4.4 (3.6, 5.2) 4.1 (3.5, 4.6) 0.55 
  Riboflavin, mg/d 1.4 1.7 (1.4, 2.0) 1.6 (1.4, 1.8) 0.49 
Vitamin B6, mg/d 1.4 1.6 (1.5, 1.8) 1.6 (1.4, 1.8) 0.73 
Biomarker statusb  cut-offc    
  RBC folate, nmol/L > 309 595 (502, 688) 662 (513, 810) 0.45 
  Serum B12, pmol/L > 172 511 (418, 605) 529 (460, 598) 0.75 
  Riboflavin, EGRacd < 1.40 1.48 (1.38, 1.58) 1.44 (1.37, 1.52) 0.54 
  Plasma homocysteine, µmol/L < 10.7 6.9 (6.1, 7.7) 6.9 (5.8, 8.0) 0.94 
Data presented as mean (95% CI), unless otherwise indicated. Differences between groups were assessed 255 
using an independent t test (continuous variables) or chi-square test (categorical variables). Statistically 256 
significant difference P < .05. 257 
aChildren who provided dietary intake data n = 48 (placebo n = 21; FA n = 27). 258 
bChildren who provided a blood sample n = 33 (placebo n = 16; FA n = 17). 259 
cPopulation reference intakes from EFSA (2017) [24] and biomarker reference ranges from Kerr et al 260 
(2009) [26]. 261 
dEGRac, erythrocyte glutathione reductase activation coefficient (biomarker of riboflavin status; a 262 
higher EGRac ratio indicates lower riboflavin status). Suboptimal riboflavin status is indicated by an 263 
EGRac value of 1.30 - 1.40 whereas ≥ 1.40 is considered deficient. 264 
 265 



































































Full Scale IQ, composite domains and subtest scores from FASSTT Offspring trial participants 267 
at 11 years are presented in Table 3 and Additional File 1: Table S2. The children of mothers 268 
randomised to FA compared with placebo during pregnancy scored significantly higher in two 269 
Processing Speed tests i.e. symbol search (+2.9 points) and cancellation (+11.3 points), whereas 270 
the positive effect of prenatal FA on Verbal Comprehension was significant in girls only (+6.5 271 
points) (Table 3). At all FASSTT Offspring Trial time-points, as currently assessed at 11 years 272 
and previously at 3 and 7 years, greater proportions of children from FA-treated mothers 273 
compared with placebo had cognitive scores above the median value of 10.0 (in the BSITD-III 274 
test at 3 years); 23.0 (in the WPPSI-III test at 7 years); 102.5 (in the WISC-IV test at 11 years); 275 
albeit by 11 years the effect of FA appeared to have diminished somewhat (Fig 2). Of note, 276 
71.4% of the children from FA-treated mothers who had cognitive scores above the median at 11 277 
years also scored above the median at 7 years and the Full Scale IQ scores at these time points 278 
were significantly correlated (r=0.463; P<0.0001).  279 
 280 
Table 3 WISC-IV cognitive assessment and MEG brain imaging in FASSTT Offspring trial 281 
participants 282 





WISC-IV assessment      
Full Scale IQ 101.5 (96.9, 106.0) 102.8 (99.5, 106.1) 1.3 (-4.1, 6.7) 0.63 0.85 
  Boys 103.2 (95.7, 110.7) 101.3 (95.6, 107.0) 1.9 (-10.9, 7.1) 0.66 0.61 
  Girls 99.9 (93.8, 106.1) 103.8 (99.5, 108.1) 3.8 (-3.2, 10.8) 0.28 0.44 
Verbal Comprehension 95.0 (90.9, 99.1) 97.5 (94.6, 100.3) 2.5 (-2.4, 7.3) 0.31 0.45 
  Boys 97.9 (89.9, 105.9) 95.2 (90.5, 99.9) 2.7 (-11.6, 6.1) 0.53 0.48 
  Girls 92.4 (88.5, 96.3) 99.0 (95.2, 102.7) 6.5 (1.2, 11.8) 0.02 0.03 
Perceptual Reasoning 106.3 (101.4, 111.2) 104.5 (100.9, 108.2) 1.8 (-7.6, 4.0) 0.54 0.45 
  Boys 107.3 (100.3, 114.3) 104.1 (97.5, 110.6) 3.2 (-12.3, 5.9) 0.47 0.51 
  Girls 105.5 (98.0, 113.0) 104.9 (100.2, 109.5) 0.6 (-8.7, 7.5) 0.87 0.85 
Working Memory 96.9 (92.3, 101.5) 98.4 (85.5, 101.3) 1.5 (-3.6, 6.6) 0.55 0.76 
  Boys 98.2 (92.1, 104.3) 98.4 (93.1, 103.7) 0.2 (-7.5, 7.8) 0.96 0.97 
  Girls 95.8 (88.6, 103.1) 98.4 (94.8, 102.0) 2.6 (-4.6, 9.8) 0.47 0.74 
Processing Speed  104.2 (98.9, 109.6) 109.2 (105.9, 112.5) 4.9 (-1.0, 10.9) 0.10 0.16 



































































  Girls 105.9 (98.2, 113.7) 109.7 (105.4, 113.9) 3.7 (-4.3, 11.7) 0.35 0.64 
  Coding subtest 47.9 (44.5, 51.3) 49.0 (46.6, 51.4) 1.1 (-2.7, 5.0) 0.78 0.73 
  Symbol search subtest 24.6 (22.3, 26.9) 27.5 (26.2, 28.8) 2.9 (0.3, 5.5) 0.03 0.03 
  Cancellation subtest 83.7 (75.8, 91.6) 95.0 (89.6, 100.3) 11.3 (2.5, 20.1) 0.05 0.04 
MEG band power in response to the language paradigmc    
Broad [1-48 Hz]d 48.9 (14.6, 83.2) 32.9 (6.7, 59.0) 16.1 (-56.6, 24.5) 0.43 0.41 
  Theta [4-8 Hz] 90.8 (38.1, 143.4) 65.3 (28.7, 102.0) 25.5 (-84.9, 34.0) 0.36 0.21 
  Mu [8-12 Hz] 53.9 (26.1, 81.6) 39.2 (15.1, 63.3) 14.6 (-49.8, 20.5) 0.39 0.46 
  Beta [13-30 Hz] 26.4 (2.7, 50.1) 109.6 (52.4, 166.8) 83.2 (15.0, 151.4) 0.02 0.01 
  Low Gamma [30-48 Hz] 40.5 (-7.6, 88.5) 45.3 (16.0, 74.5) 4.8 (-46.5, 56.1) 0.49 0.39 
High Gamma [49-70 Hz] 30.1 (-4.4, 64.6) 100.8 (48.6, 153.0) 70.7 (6.5, 135.0) 0.04 0.04 
Data presented as mean (95% CI), unless otherwise indicated. Differences between groups were analysed 283 
by aindependent t-test or bANCOVA adjusting for covariates: Multiple Deprivation Measure and child’s 284 
sex. Statistically significant difference p < .05. 285 
cMEG analysis completed in a subset of children: Placebo, n=14; Folic acid, n=19. Differences between 286 
groups were analysed by aindependent t-test or bANCOVA adjusting for child’s sex.  287 
dBroad band [1-48 Hz] is comprised of Theta, Mu, Beta and Low Gamma bands. 288 
 289 
Fig. 2 Percentage of FASSTT Offspring participants at 3, 7 and 11 years achieving above average 290 
cognitive performance by treatment allocation of the mother during pregnancy.  291 
In children at 3 years, cognitive performance was assessed by the BSITD-III test, at 7 years by the WPPSI-292 
III test, and at 11 years by the WISC-IV test. Values are % of children at 3, 7 or 11 years, by treatment 293 
group of the mother, who achieved above the median cognitive score for children at that age (relative to 294 
those who scored at and below the median score); median scores are 10.0 in the BSITD-III test; 23.0 in 295 
the WPPSI-III test; 102.5 in the WISC-IV test. Total participants numbers at each age are: 3 years, n=39; 296 
7 years, n=70; 11 years, n=68. 71.4% of the children from FA-treated mothers who had cognitive scores 297 
above the median at 11 years also scored above the median at 7 years and Full Scale IQ scores at these 298 
time points were significantly correlated (r=0.463; P<0.0001). 299 
 300 
Effects of maternal FA intervention on child brain function response 301 
MEG brain imaging was offered to all the participants in the trial, but owing to practical 302 
considerations (including the requirement to undertake a 2-hour return journey to our NIFBM 303 
centre), not all children participated in this component. Of the 68 mother-child pairs in the current 304 
follow-up study, 33 children also completed the MEG assessment. Maternal characteristics 305 



































































FASSTT trial participants (Additional File 1: Table S3). MEG assessment of neuronal 307 
responses to a language task showed increased power at the Beta (13-30 Hz) and High Gamma 308 
(49-70 Hz) bands in children from FA-supplemented mothers compared to placebo, indicating 309 
predominant involvement of local neurons, and in turn, more efficient semantic processing of 310 
language (Table 3). Given that the MEG brain imagining was conducted only in a subset of 311 
children (i.e. 49% of child participants), the MEG results were not analysed by sex. 312 
In addition, power at the Beta band in children was significantly correlated with maternal 313 
serum and RBC folate concentrations at the 36th GW of pregnancy (r=0.439, p=0.02; n=33 and 314 
r=0.393, p=0.03; n=32, respectively). Furthermore, when maternal serum folate at the 36th GW 315 
was dichotomised into lower and higher status categories based on the median value, higher 316 
maternal folate was associated with significantly higher power at the Beta (mean difference 90.7 317 
points, 95% CI 22.5 to 158.9, p=0.002), but not High Gamma (14.8, -85.9 to 56.3, p=0.99), band 318 
in the child at 11 years, after adjustment for the child’s sex and socioeconomic status. Similar 319 
correlations for cord blood folate status with MEG were found, specifically, serum folate was 320 
significantly associated with power at the Beta band (r=0.439, p=0.03, n=26). Likewise, in 321 
children with higher cord blood folate, we found significantly higher power at the Beta band 322 
(65.0, 95% CI -10.4 to 140.4, p=0.05) at 11 years. 323 
 324 
Discussion  325 
We examined the effect of FA intervention in trimesters 2 and 3 of pregnancy in women taking 326 
FA as recommended in the first trimester, and provide the first randomised trial evidence that 327 
continued FA supplementation (400 µg/d) throughout pregnancy can influence cognitive 328 
performance and brain function of the child up to 11 years of age. The results not only provide a 329 



































































cognitive benefits in these children at 3 and 7 years, but provide the first MEG brain imaging 331 
evidence that FA supplementation in pregnancy can impact brain function in the child. 332 
Our results, reporting the third follow-up of mother-child pairs from the FASSTT trial, 333 
show that the 11-year old children of mothers randomised to FA compared with placebo during 334 
trimesters 2 and 3 of pregnancy scored significantly higher in specified cognitive IQ domains of 335 
the WISC-IV assessment, namely, two Processing Speed tests, i.e. symbol search (by 2.9 points) 336 
and cancellation (by 11.3 points), and Verbal Comprehension (by 6.5 points) in girls. The results 337 
are entirely consistent with our earlier findings in these children at a younger age, showing higher 338 
scores in overall cognition at 3 years and in verbal IQ at 7 years in the offspring of FA-treated 339 
mothers in pregnancy [11]. Here we show that at all time-points up to age 11 years, greater 340 
proportions of children from FA-treated mothers, compared with placebo, had cognitive scores 341 
above the median values of 10.0 in the BSITD-III test (at 3 years); 23.0 in the WPPSI-III test (at 342 
7 years); 102.5 in the WISC-IV test (at 11 years). The FASSTT Offspring trial thus provides 343 
more robust evidence of the role of maternal folate status in offspring cognitive function 344 
compared with previous observational studies that have reported positive associations between 345 
FA use in early pregnancy (as retrospectively reported by mothers) or maternal folate 346 
concentrations, and cognitive performance in the child [6, 28, 29]. The role of maternal folate 347 
beyond the first trimester of pregnancy has been far less frequently investigated in previous 348 
studies, but one notable study found that higher plasma folate at the 30th gestational week was 349 
associated with better cognitive performance in over 500 children aged 9-10 years in South India 350 
[8]. Our results are thus consistent with previous observations, but add considerably to the 351 
evidence, and indicate that FA intervention throughout pregnancy will have beneficial effects on 352 
cognitive performance in the child in up 11 years. Of note, folate intake and status of the children 353 



































































comparing favourably with reference values for this age group [24] and biomarker concentrations 355 
in good agreement with those reported in children from Norway [25], UK [26] and USA [27].  356 
The current sex-specific findings, showing a positive effect of prenatal FA on verbal IQ 357 
in 11-year old girls (by 6.5 points), but not in boys, are not entirely unexpected given existing 358 
evidence of sex differences in brain activity patterns associated with cognition and behaviour, 359 
and in functional brain development in infancy and early childhood [4]. Also, between 3 and 60 360 
months, females are reported to exhibit a higher rate of myelination than do males in the genu of 361 
the corpus callosum, in left frontal and left temporal white matter and in the right optic radiation 362 
[30]. Furthermore, in previous epigenetic analysis of cord samples from these children at birth, 363 
we investigated candidate genes related to brain development or function and reported significant 364 
DNA methylation effects in IGF2 in girls, but not in boys, arising from maternal FA intervention 365 
[31], perhaps offering a biological basis for the sex-differences found here in the relationship of 366 
prenatal FA with cognitive outcomes in childhood. Sex differences in brain development, 367 
however, likely reflect a dynamic interplay of many biological (e.g. prenatal and neonatal 368 
hormone production and direct sex chromosome effects) and other mechanisms [4]. In any case, 369 
this aspect requires further investigation. 370 
In addition to using standardised IQ tests to measure child cognition, we applied 371 
magnetoencephalographic brain imaging for the first time in a study of this kind. In broad support 372 
of the cognitive outcomes, the neuronal activity assessments using MEG indicated more efficient 373 
semantic processing of language in the 11-year old child as a result of prenatal intervention with 374 
FA. Specifically, the increased power at Beta and High Gamma bands in response to the language 375 
task in children from the FA group suggest more active engagement of local neuronal networks. 376 
Previously, increased power at the High Gamma band using MEG was reported as a result of 377 
intensive computer-based training [32]. The fact that we observed similar band power patterns 378 



































































children with enhanced cognition as a consequence of intensive training, suggests that the current 380 
MEG findings are clinically relevant.  381 
The finding of FA-related effects in language processing as assessed by MEG is broadly 382 
in line with the higher verbal comprehension scores in the current WISC-IV assessment at 11 383 
years and our earlier findings of higher verbal IQ in these children at 7 years in response to 384 
prenatal FA. Likewise, a recent study reported greater cerebral cortical thickness in children aged 385 
8-18 years who were exposed prenatally to population-wide FA fortification compared to those 386 
born before the introduction of this mandatory policy in the USA [33], whilst in the Generation 387 
R Study, maternal folate deficiency diagnosed after the first trimester was associated with 388 
reduced brain volume (measured using magnetic resonance imaging) in 6-8 year old Dutch 389 
children [9].  Thus, our randomised trial results, together with the available observational 390 
evidence, are consistent in indicating that prenatal maternal FA supplementation affects 391 
neurocognitive development and may have a specific role in semantic processing of language up 392 
to 11 years. In addition, there may be clinical implications of our findings for later life in that the 393 
achievement of full cognitive potential of the child is considered paramount for future academic 394 
attainment, and higher intelligence in childhood is associated with better cognitive reserves in 395 
adulthood that could potentially delay cognitive decline in later life [34, 35]. Future MEG studies 396 
might investigate the functional neural connectivity patterns within emerging neural networks, 397 
both in resting-state and under task conditions, that support developing language and cognition. 398 
Although the precise mechanism explaining the effect of FA during pregnancy on 399 
neurodevelopment of the child is unknown, it must in some way involve the essential role of 400 
folate in one-carbon metabolism, encompassing a complex network of interdependent pathways 401 
required for a number of biological processes that could impact neurodevelopment, including 402 
myelination, neurotransmitter synthesis and methylation [36]. It is also possible that folate-403 



































































of cord blood samples in these children as newborns, using a candidate gene approach we showed 405 
that prenatal FA throughout pregnancy resulted in significant effects in DNA methylation in 406 
specific genes linked with brain development or function (IGF2, BDNF and the widely dispersed 407 
retrotransposon, LINE-1) [31], and in epigenome-wide screening of the same samples, we 408 
identified a novel mechanism for folate-dependent regulation of the ZFP57 gene [37].  409 
The main strength of this study is the research design, involving a follow-up study in 410 
children of mothers who had participated in a randomised trial in pregnancy, which enabled the 411 
demonstration of a causative link between prenatal FA and subsequent neurocognitive 412 
development in the child. The use in a sub-set of children of the neuroimaging technique, MEG, 413 
objectively investigated the effects of FA intervention in pregnancy on brain function in 414 
childhood. Furthermore, this is the third follow-up of the FASSTT Offspring cohort (with 415 
previous investigations at age 3 and 7 years), providing the opportunity to track cognitive 416 
development in childhood, and the broad agreement in results at all time-points provides some 417 
degree of internal validation to the findings. In addition, a range of factors previously reported to 418 
be associated with cognitive performance, and thus potential confounders in the relationship 419 
between prenatal FA and offspring intelligence, were considered [23, 38]. However, this study 420 
also has limitations, the most notable of which is the relatively small sample size. Although every 421 
effort was made to maximise the participation rate from the original FASSTT trial (n=119), the 422 
final sample of 68 mother-child pairs may have lacked sufficient statistical power to detect small 423 
differences in some components of the WISC-IV cognitive test. Also paternal factors, recently 424 
emerging as potentially important for child neurocognitive development, were not considered. 425 
 426 
Conclusions 427 
In summary, our findings in the children of participants in a randomised trial in pregnancy add 428 



































































status in pregnancy with neurocognitive outcomes in the child. We examined the effect of FA 430 
intervention in trimesters 2 and 3 of pregnancy (in women taking FA as recommended in the first 431 
trimester), and provide the first randomised trial evidence that continued FA supplementation 432 
(400 µg/d) throughout pregnancy can influence cognitive performance and brain function of the 433 
child up to 11 years of age. In addition to using standardised IQ tests to measure child cognition, 434 
we applied magnetoencephalographic brain imaging for the first time in a study of this kind, and 435 
the findings not only reinforce our previous findings of cognitive benefits in these children at 3 436 
and 7 years, but provide new evidence of a specific role of prenatal FA in semantic processing 437 
of language. The totality of evidence has important impacts in informing new policy and clinical 438 
practice in relation to FA use in pregnancy. Whereas current recommendations for NTD 439 
prevention in the UK and most countries worldwide advise mothers to take FA supplements from 440 
before conceiving until the end of the 12th gestational week only, our findings suggest that 441 
continued FA intervention in pregnancy beyond the early period required to prevent NTD is 442 
beneficial to neurocognitive development in the child. In a wider context, we demonstrate the 443 
application of MEG as a non-invasive tool in paediatric research to objectively assess functional 444 
brain activity in response to nutrition and other interventions. 445 
 446 
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Additional File 1: Methods. Supplementary details in relation to magnetoencephalographic 
brain imaging. Table S1. Maternal characteristics during pregnancy in all FASSTT trial 
participants and in the sample whose children completed the FASSTT Offspring trial at 11 
years. Table S2. Full Scale IQ, composite and subtest scores for the WISC-IV cognitive 
assessment in FASSTT Offspring trial participants. Table S3. Maternal characteristics during 
pregnancy in all FASSTT trial participants and in the sub-sample whose children completed 

































































































Mother-child pairs  





Women taking folic acid supplementation 
in the first trimester (n=248) 
Eligible participants start the FASSTT 
trial at 14th gestational week (n=226) 
Women not taking folic 
acid supplements (n=48) 
Total available sample of pregnant women (n=296)  
Participant withdrawal (n=11) 
Pregnancy complications (n=13) 
Prescribed folic acid (n=16) 
Fetal death (n=4) 
Noncompliance (n=3) 
Transfer to another hospital (n=0) 




Folic Acid  
(n=37) 
Not available for sampling at 11y 
Not interested (n=22) 
Not available (n=14) 
Uncontactable (n=9)  
Emigrated abroad (n=6) 




























Participant withdrawal (n=14) 
Pregnancy complications (n=8) 
Prescribed folic acid (n=5) 
Fetal death (n=2) 
Noncompliance (n=3) 
Transfer to another hospital (n=2) 

































Cognitive score (BSID-III)  
7 years  
Full Scale IQ (WPPSI-III)  
 
11 years  
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